New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
Identifieur interne : 000A40 ( PubMed/Curation ); précédent : 000A39; suivant : 000A41New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
Auteurs : Gregory A. Poland [États-Unis] ; Douglas M. Fleming ; John J. Treanor ; Eugene Maraskovsky ; Thomas C. Luke ; Emma M A. Ball ; Caroline M. PolandSource :
- Vaccine [ 1873-2518 ] ; 2013.
Descripteurs français
- KwdFr :
- Acceptation des soins par le patient, Adjuvants immunologiques (administration et posologie), Adjuvants immunologiques (pharmacologie), Animaux, Association médicamenteuse, Cholestérol (administration et posologie), Congrès comme sujet, Enfant, Enfant d'âge préscolaire, Espagne, Furets, Grippe humaine (), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains, Immunisation passive (), Immunoglobulines par voie veineuse (usage thérapeutique), Infections à Orthomyxoviridae (), Modèles animaux de maladie humaine, Pandémie de grippe de 1918-1919, Pandémies, Phospholipides (administration et posologie), Saponines (administration et posologie), Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A, Vaccination (psychologie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (usage thérapeutique), Vaccins inactivés (effets indésirables).
- MESH :
- administration et posologie : Adjuvants immunologiques, Cholestérol, Phospholipides, Saponines, Vaccins antigrippaux.
- effets indésirables : Vaccins antigrippaux, Vaccins inactivés.
- immunologie : Vaccins antigrippaux.
- pharmacologie : Adjuvants immunologiques.
- psychologie : Vaccination.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Immunoglobulines par voie veineuse, Vaccins antigrippaux.
- virologie : Grippe humaine.
- épidémiologie : Grippe humaine.
- Acceptation des soins par le patient, Animaux, Association médicamenteuse, Congrès comme sujet, Enfant, Enfant d'âge préscolaire, Espagne, Furets, Grippe humaine, Humains, Immunisation passive, Infections à Orthomyxoviridae, Modèles animaux de maladie humaine, Pandémie de grippe de 1918-1919, Pandémies, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adjuvants, Immunologic (pharmacology), Animals, Child, Child, Preschool, Cholesterol (administration & dosage), Congresses as Topic, Disease Models, Animal, Drug Combinations, Ferrets, Humans, Immunization, Passive (methods), Immunoglobulins, Intravenous (therapeutic use), Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza A Virus, H5N1 Subtype, Influenza Pandemic, 1918-1919, Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (virology), Orthomyxoviridae Infections (prevention & control), Pandemics, Patient Acceptance of Health Care, Phospholipids (administration & dosage), Saponins (administration & dosage), Spain, Vaccination (psychology), Vaccines, Inactivated (adverse effects).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Cholesterol, Influenza Vaccines, Phospholipids, Saponins.
- chemical , adverse effects : Influenza Vaccines, Vaccines, Inactivated.
- chemical , immunology : Influenza Vaccines.
- chemical , pharmacology : Adjuvants, Immunologic.
- drug therapy : Influenza, Human.
- epidemiology : Influenza, Human.
- methods : Immunization, Passive.
- prevention & control : Influenza, Human, Orthomyxoviridae Infections.
- psychology : Vaccination.
- chemical , therapeutic use : Immunoglobulins, Intravenous, Influenza Vaccines.
- virology : Influenza, Human.
- Animals, Child, Child, Preschool, Congresses as Topic, Disease Models, Animal, Drug Combinations, Ferrets, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza A Virus, H5N1 Subtype, Influenza Pandemic, 1918-1919, Pandemics, Patient Acceptance of Health Care, Spain.
Abstract
Both seasonal and pandemic influenza cause considerable morbidity and mortality globally. In addition, the ongoing threat of new, unpredictable influenza pandemics from emerging variant strains cannot be underestimated. Recently bioCSL (previously known as CSL Biotherapies) sponsored a symposium 'New Wisdom to Defy an Old Enemy' at the 4th Influenza Vaccines for the World Congress in Valencia, Spain. This symposium brought together a renowned faculty of experts to discuss lessons from past experience, novel influenza vaccine developments, and new methods to increase vaccine acceptance and coverage. Specific topics reviewed and discussed included new vaccine development efforts focused on improving efficacy via alternative administration routes, dose modifications, improved adjuvants, and the use of master donor viruses. Improved safety was also discussed, particularly the new finding of an excess of febrile reactions isolated to children who received the 2010 Southern Hemisphere (SH) trivalent inactivated influenza vaccine (TIV). Significant work has been done to both identify the cause and minimize the risk of febrile reactions in children. Other novel prophylactic and therapeutic advances were discussed including immunotherapy. Standard IVIg and hIVIg have been used in ferret studies and human case reports with promising results. New adjuvants, such as ISCOMATRIX™ adjuvant, were noted to provide single-dose, prolonged protection with seasonal vaccine after lethal H5N1 virus challenge in a ferret model of human influenza disease. The data suggest that adjuvanted seasonal influenza vaccines may provide broader protection than unadjuvanted vaccines. The use of an antigen-formulated vaccine to induce broad protection between pandemics that could bridge the gap between pandemic declaration and the production of a homologous vaccine was also discussed. Finally, despite the availability of effective vaccines, most current efforts to increase influenza vaccine coverage rates to higher levels (i.e., above 70-80%) have been ineffective in highly developed countries where the vaccine is used, hindered by the public's skepticism towards vaccines in general. New educational and social media methods to increase vaccine acceptance and coverage were discussed. While the first priority should be the development of improved influenza vaccines, a particular focus on the aging global population is critical. It is also important to draw lessons from other academic disciplines that can help to inform vaccine education programs, policy, and communication. By tailoring communications and patient education using an understanding of cognitive bias and the model of preferred cognitive styles, the likelihood of effecting desirable health decisions can be maximized, leading to improved vaccine coverage and control of influenza and other vaccine-preventable diseases.
DOI: 10.1016/j.vaccine.2013.02.033
PubMed: 23587330
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A40
Links to Exploration step
pubmed:23587330Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.</title>
<author><name sortKey="Poland, Gregory A" sort="Poland, Gregory A" uniqKey="Poland G" first="Gregory A" last="Poland">Gregory A. Poland</name>
<affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. poland.gregory@mayo.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fleming, Douglas M" sort="Fleming, Douglas M" uniqKey="Fleming D" first="Douglas M" last="Fleming">Douglas M. Fleming</name>
</author>
<author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J" last="Treanor">John J. Treanor</name>
</author>
<author><name sortKey="Maraskovsky, Eugene" sort="Maraskovsky, Eugene" uniqKey="Maraskovsky E" first="Eugene" last="Maraskovsky">Eugene Maraskovsky</name>
</author>
<author><name sortKey="Luke, Thomas C" sort="Luke, Thomas C" uniqKey="Luke T" first="Thomas C" last="Luke">Thomas C. Luke</name>
</author>
<author><name sortKey="Ball, Emma M A" sort="Ball, Emma M A" uniqKey="Ball E" first="Emma M A" last="Ball">Emma M A. Ball</name>
</author>
<author><name sortKey="Poland, Caroline M" sort="Poland, Caroline M" uniqKey="Poland C" first="Caroline M" last="Poland">Caroline M. Poland</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23587330</idno>
<idno type="pmid">23587330</idno>
<idno type="doi">10.1016/j.vaccine.2013.02.033</idno>
<idno type="wicri:Area/PubMed/Corpus">000A40</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A40</idno>
<idno type="wicri:Area/PubMed/Curation">000A40</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A40</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.</title>
<author><name sortKey="Poland, Gregory A" sort="Poland, Gregory A" uniqKey="Poland G" first="Gregory A" last="Poland">Gregory A. Poland</name>
<affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. poland.gregory@mayo.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fleming, Douglas M" sort="Fleming, Douglas M" uniqKey="Fleming D" first="Douglas M" last="Fleming">Douglas M. Fleming</name>
</author>
<author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J" last="Treanor">John J. Treanor</name>
</author>
<author><name sortKey="Maraskovsky, Eugene" sort="Maraskovsky, Eugene" uniqKey="Maraskovsky E" first="Eugene" last="Maraskovsky">Eugene Maraskovsky</name>
</author>
<author><name sortKey="Luke, Thomas C" sort="Luke, Thomas C" uniqKey="Luke T" first="Thomas C" last="Luke">Thomas C. Luke</name>
</author>
<author><name sortKey="Ball, Emma M A" sort="Ball, Emma M A" uniqKey="Ball E" first="Emma M A" last="Ball">Emma M A. Ball</name>
</author>
<author><name sortKey="Poland, Caroline M" sort="Poland, Caroline M" uniqKey="Poland C" first="Caroline M" last="Poland">Caroline M. Poland</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Adjuvants, Immunologic (pharmacology)</term>
<term>Animals</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cholesterol (administration & dosage)</term>
<term>Congresses as Topic</term>
<term>Disease Models, Animal</term>
<term>Drug Combinations</term>
<term>Ferrets</term>
<term>Humans</term>
<term>Immunization, Passive (methods)</term>
<term>Immunoglobulins, Intravenous (therapeutic use)</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza A Virus, H5N1 Subtype</term>
<term>Influenza Pandemic, 1918-1919</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Pandemics</term>
<term>Patient Acceptance of Health Care</term>
<term>Phospholipids (administration & dosage)</term>
<term>Saponins (administration & dosage)</term>
<term>Spain</term>
<term>Vaccination (psychology)</term>
<term>Vaccines, Inactivated (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acceptation des soins par le patient</term>
<term>Adjuvants immunologiques (administration et posologie)</term>
<term>Adjuvants immunologiques (pharmacologie)</term>
<term>Animaux</term>
<term>Association médicamenteuse</term>
<term>Cholestérol (administration et posologie)</term>
<term>Congrès comme sujet</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Espagne</term>
<term>Furets</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Immunisation passive ()</term>
<term>Immunoglobulines par voie veineuse (usage thérapeutique)</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Modèles animaux de maladie humaine</term>
<term>Pandémie de grippe de 1918-1919</term>
<term>Pandémies</term>
<term>Phospholipides (administration et posologie)</term>
<term>Saponines (administration et posologie)</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccination (psychologie)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
<term>Vaccins inactivés (effets indésirables)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Cholesterol</term>
<term>Influenza Vaccines</term>
<term>Phospholipids</term>
<term>Saponins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Cholestérol</term>
<term>Phospholipides</term>
<term>Saponines</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Passive</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunoglobulins, Intravenous</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Immunoglobulines par voie veineuse</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Congresses as Topic</term>
<term>Disease Models, Animal</term>
<term>Drug Combinations</term>
<term>Ferrets</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza A Virus, H5N1 Subtype</term>
<term>Influenza Pandemic, 1918-1919</term>
<term>Pandemics</term>
<term>Patient Acceptance of Health Care</term>
<term>Spain</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Acceptation des soins par le patient</term>
<term>Animaux</term>
<term>Association médicamenteuse</term>
<term>Congrès comme sujet</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Espagne</term>
<term>Furets</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Immunisation passive</term>
<term>Infections à Orthomyxoviridae</term>
<term>Modèles animaux de maladie humaine</term>
<term>Pandémie de grippe de 1918-1919</term>
<term>Pandémies</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Both seasonal and pandemic influenza cause considerable morbidity and mortality globally. In addition, the ongoing threat of new, unpredictable influenza pandemics from emerging variant strains cannot be underestimated. Recently bioCSL (previously known as CSL Biotherapies) sponsored a symposium 'New Wisdom to Defy an Old Enemy' at the 4th Influenza Vaccines for the World Congress in Valencia, Spain. This symposium brought together a renowned faculty of experts to discuss lessons from past experience, novel influenza vaccine developments, and new methods to increase vaccine acceptance and coverage. Specific topics reviewed and discussed included new vaccine development efforts focused on improving efficacy via alternative administration routes, dose modifications, improved adjuvants, and the use of master donor viruses. Improved safety was also discussed, particularly the new finding of an excess of febrile reactions isolated to children who received the 2010 Southern Hemisphere (SH) trivalent inactivated influenza vaccine (TIV). Significant work has been done to both identify the cause and minimize the risk of febrile reactions in children. Other novel prophylactic and therapeutic advances were discussed including immunotherapy. Standard IVIg and hIVIg have been used in ferret studies and human case reports with promising results. New adjuvants, such as ISCOMATRIX™ adjuvant, were noted to provide single-dose, prolonged protection with seasonal vaccine after lethal H5N1 virus challenge in a ferret model of human influenza disease. The data suggest that adjuvanted seasonal influenza vaccines may provide broader protection than unadjuvanted vaccines. The use of an antigen-formulated vaccine to induce broad protection between pandemics that could bridge the gap between pandemic declaration and the production of a homologous vaccine was also discussed. Finally, despite the availability of effective vaccines, most current efforts to increase influenza vaccine coverage rates to higher levels (i.e., above 70-80%) have been ineffective in highly developed countries where the vaccine is used, hindered by the public's skepticism towards vaccines in general. New educational and social media methods to increase vaccine acceptance and coverage were discussed. While the first priority should be the development of improved influenza vaccines, a particular focus on the aging global population is critical. It is also important to draw lessons from other academic disciplines that can help to inform vaccine education programs, policy, and communication. By tailoring communications and patient education using an understanding of cognitive bias and the model of preferred cognitive styles, the likelihood of effecting desirable health decisions can be maximized, leading to improved vaccine coverage and control of influenza and other vaccine-preventable diseases.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23587330</PMID>
<DateCompleted><Year>2014</Year>
<Month>02</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>31 Suppl 1</Volume>
<PubDate><Year>2013</Year>
<Month>Apr</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.</ArticleTitle>
<Pagination><MedlinePgn>A1-20</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2013.02.033</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(13)00196-5</ELocationID>
<Abstract><AbstractText>Both seasonal and pandemic influenza cause considerable morbidity and mortality globally. In addition, the ongoing threat of new, unpredictable influenza pandemics from emerging variant strains cannot be underestimated. Recently bioCSL (previously known as CSL Biotherapies) sponsored a symposium 'New Wisdom to Defy an Old Enemy' at the 4th Influenza Vaccines for the World Congress in Valencia, Spain. This symposium brought together a renowned faculty of experts to discuss lessons from past experience, novel influenza vaccine developments, and new methods to increase vaccine acceptance and coverage. Specific topics reviewed and discussed included new vaccine development efforts focused on improving efficacy via alternative administration routes, dose modifications, improved adjuvants, and the use of master donor viruses. Improved safety was also discussed, particularly the new finding of an excess of febrile reactions isolated to children who received the 2010 Southern Hemisphere (SH) trivalent inactivated influenza vaccine (TIV). Significant work has been done to both identify the cause and minimize the risk of febrile reactions in children. Other novel prophylactic and therapeutic advances were discussed including immunotherapy. Standard IVIg and hIVIg have been used in ferret studies and human case reports with promising results. New adjuvants, such as ISCOMATRIX™ adjuvant, were noted to provide single-dose, prolonged protection with seasonal vaccine after lethal H5N1 virus challenge in a ferret model of human influenza disease. The data suggest that adjuvanted seasonal influenza vaccines may provide broader protection than unadjuvanted vaccines. The use of an antigen-formulated vaccine to induce broad protection between pandemics that could bridge the gap between pandemic declaration and the production of a homologous vaccine was also discussed. Finally, despite the availability of effective vaccines, most current efforts to increase influenza vaccine coverage rates to higher levels (i.e., above 70-80%) have been ineffective in highly developed countries where the vaccine is used, hindered by the public's skepticism towards vaccines in general. New educational and social media methods to increase vaccine acceptance and coverage were discussed. While the first priority should be the development of improved influenza vaccines, a particular focus on the aging global population is critical. It is also important to draw lessons from other academic disciplines that can help to inform vaccine education programs, policy, and communication. By tailoring communications and patient education using an understanding of cognitive bias and the model of preferred cognitive styles, the likelihood of effecting desirable health decisions can be maximized, leading to improved vaccine coverage and control of influenza and other vaccine-preventable diseases.</AbstractText>
<CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poland</LastName>
<ForeName>Gregory A</ForeName>
<Initials>GA</Initials>
<AffiliationInfo><Affiliation>Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. poland.gregory@mayo.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fleming</LastName>
<ForeName>Douglas M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Treanor</LastName>
<ForeName>John J</ForeName>
<Initials>JJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Maraskovsky</LastName>
<ForeName>Eugene</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Luke</LastName>
<ForeName>Thomas C</ForeName>
<Initials>TC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ball</LastName>
<ForeName>Emma M A</ForeName>
<Initials>EM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Poland</LastName>
<ForeName>Caroline M</ForeName>
<Initials>CM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493786">ISCOMATRIX</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012503">Saponins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber>
<NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Vaccine. 2013 Dec 17;32(1):2-3</RefSource>
<PMID Version="1">24035589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Vaccine. 2013 Dec 17;32(1):1</RefSource>
<PMID Version="1">24055086</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003226" MajorTopicYN="N">Congresses as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064149" MajorTopicYN="N">Influenza Pandemic, 1918-1919</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012503" MajorTopicYN="N">Saponins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>01</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>02</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>4</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>2</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23587330</ArticleId>
<ArticleId IdType="pii">S0264-410X(13)00196-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2013.02.033</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000A40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:23587330 |texte= New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23587330" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |